heart
-
Sanofi chooses Burgopak slider design for heartburn treatment
Sanofi has chosen the award-winning Burgopak slider design for its heartburn treatment, Maalox Plus, which was launched into the Italian market this year.
heart | 31 October 2011
-
Getting to the heart of CVD
Cardiovascular diseases are the world’s leading cause of death. Experts and journalists from around the world converge on Beijing for the World Congress of Cardiology Bayer scientific roundtable to discuss the problem. LEE KOK LEONG travels to China to report.
heart | 01 August 2010
-
Watson Receives Approval for Heart Failure Drug
Watson Laboratories has received approval from the US Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for metoprolol succinate extended-release tablets USP in the 100 and 200 mg strengths, the generic equivalent to A…
heart | 22 April 2010
-
Roche Announces Early Closure of Heart Failure Trial
Roche and study investigators at the Massachusetts General Hospital have announced that active enrollment into the Pro-BNP Outpatient Tailored Congestive Heart Failure Therapy (PROTECT) study has been stopped early based on a positive interim analysi…
heart | 24 December 2009
-
Angina Drug Reduces Incidences of Heart Attack
Findings in patients with angina who participated in the Beautiful study, show that there is a 42 percent reduction in heart attack with Procoralan (ivabradine). This benefit was particularly marked in patients with a resting heart rate >= 70 beats p…
heart | 18 September 2009
-
Blood Pump for Simulating the Ventricular Action of the Heart
Harvard Apparatus has introduced the Pulsatile Blood Pump for cardiovascular and haemodynamic studies on mice, rats, and larger animals. The pump is ideal for moving emulsions, suspensions, and non-Newtonian fluids such as blood. It simulates the …
heart | 11 September 2009
-
Cholesterol Drug Cuts Heart Risk
Data from a study presented at the American Heart Association Scientific Sessions demonstrated that Crestor (rosuvastatin calcium) reduced major cardiovascular (CV) events by 44% compared to placebo. It also reduced the combined risk of cardiovascula…
heart | 30 December 2008
-
Telmisartan as effective as Ramipril but with better long-term tolerability
New results from the landmark ONTARGET Trial show that, in Asian patients at high risk of cardiovascular disease (CVD), telmisartan (Micardis) 80mg is as effective as, and significantly better tolerated than, ramipril 10mg in reducing the risk of car…
heart | 27 October 2008
-
NZ and Singapore set up first joint R&D research fund in heart disease and cancer
Singapore’s Agency for Science, Technology and Research (A*STAR) has teamed up with the Health Research Council of New Zealand (HRC) to launch the new A*STAR-NZ Joint Research Fund worth $2.31 million for research in heart disease and cancer. T…
heart | 20 October 2008
-
Omega-3 Acid Ethyl Esters Reduced Incidence of Death in Heart Failure Patients
Results from the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI) Heart Failure (GISSI-HF) study show that 1 g/d dose of omega-3 fatty acid ethyl esters reduces all causes for mortality and hospital admissions …
heart | 01 October 2008
